U.S., Oct. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07855250) titled 'An Open-label DDI Study to Investigate the Effect of Rilzabrutinib on P-gp, BCRP, OATP1B1 and OATP1B3 Inhibition' on Sept. 21.
Brief Summary: The study is a single-center, Phase-1, open-label, one-sequence, two-treatment period, cross-over, DDI study designed to investigate the effects of rilzabrutinib on the PK of digoxin (as P-gp substrate) and of rosuvastatin (as substrate of BCRP, OATP1B1, and OATP1B3) in healthy male and female participants. For this study a cocktail of digoxin and rosuvastatin will be used.
Study Start Date: Oct. 01
Study Type: INTERVENTIONAL
Condition:
Healthy Volunteer
Intervention:
DRUG: Rilzabrutinib...